NCT05627219 Extending Prostate Genetic Awareness, Navigation, and Delivery: The EXPAND Network
| NCT ID | NCT05627219 |
| Status | Recruiting |
| Phase | — |
| Sponsor | Thomas Jefferson University |
| Condition | Metastatic Prostate Carcinoma |
| Study Type | OBSERVATIONAL |
| Enrollment | 30 participants |
| Start Date | 2024-06-03 |
| Primary Completion | 2027-07 |
Eligibility & Interventions
Eligibility Fast-Check
Enter your details for a quick preliminary check. This does not replace medical advice.
What to Expect as a Participant
This is an observational study. You will not receive an experimental treatment; researchers will collect data based on your existing condition or standard treatment.
This trial targets 30 participants in total. It began in 2024-06-03 with a primary completion date of 2027-07.
⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.
Brief Summary
This trial evaluates whether a network of peer genetic coaches is useful for addressing disparities in genetic testing and screening among African American men with prostate cancer that has spread from where it first started (primary site) to other places in the body (metastatic). While genetic testing has become central to prostate cancer care, African American men are less likely seek testing due to lack of awareness, cultural beliefs, financial limitations, fear of discrimination, and mistrust in the healthcare system. A network of peer genetic coaches may help address barriers, beliefs, and needs of African American men in the community and provide navigation to increase engagement in genetic testing.
Eligibility Criteria
Inclusion Criteria: * AIM 1: Are 18 years old or older * AIM 1: Are able to read and speak English comfortably * AIM 1: Men who have experience with both prostate cancer (PCA) and genetic counseling and testing will be a priority for training, as well as men who have considerable peer education or navigation experience * AIM 2: Are 18 years old or older * AIM 2: Are African American * AIM 2: Are able to read and speak English comfortably * AIM 2: Men who meet any one of the following criteria: (1) metastatic prostate cancer; (2) prostate cancer with high-risk features (T3 or higher, Gleason 8 or higher, node positive disease); (3) with or without a diagnosis of prostate cancer with strong family history (2 or more first-degree or second-degree relatives) with prostate cancer (particularly metastatic prostate cancer or died from prostate cancer), breast cancer, ovarian cancer, pancreatic cancer, colorectal cancer, uterine cancer, renal cancer, urothelial cancer, or upper bowel cancer Exclusion Criteria: * Patients that do not meet the inclusion criteria * Children under the age of 18 * Anyone who has trouble understanding the consent or with significant anxiety detected during the consent process
Contact & Investigator
Amy Leader, DrPh, MPH
PRINCIPAL INVESTIGATOR
Thomas Jefferson University
Frequently Asked Questions
Who can join the NCT05627219 clinical trial?
This trial is open to male participants only, aged 18 Years or older, studying Metastatic Prostate Carcinoma. Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.
Is NCT05627219 currently recruiting?
Yes, NCT05627219 is actively recruiting participants. Contact the research team at ONCTrialNow@jefferson.edu for enrollment information.
Where is the NCT05627219 trial being conducted?
This trial is being conducted at Philadelphia, United States.
Who is sponsoring the NCT05627219 clinical trial?
NCT05627219 is sponsored by Thomas Jefferson University. The principal investigator is Amy Leader, DrPh, MPH at Thomas Jefferson University. The trial plans to enroll 30 participants.